Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 2
2011 2
2012 1
2013 1
2014 4
2015 4
2016 3
2017 4
2018 4
2019 1
2020 1
2021 5
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Comparing different robots available in the European market for the preparation of injectable chemotherapy and recommendations to users.
Cerutti A, Ledoux T, Vantard N, Cerfon MA, Kimbidima R, Larbre V, Herledan C, Lattard C, Baudouin A, Caffin AG, Schwiertz V, Ranchon F, Rioufol C. Cerutti A, et al. Among authors: vantard n. J Oncol Pharm Pract. 2023 Oct;29(7):1599-1612. doi: 10.1177/10781552221143786. Epub 2022 Dec 14. J Oncol Pharm Pract. 2023. PMID: 36999226 Review.
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
Aussedat G, Maucort-Boulch D, Rey P, Safar V, Karlin L, Elsensohn MH, Bachy E, Lebras L, Favier B, Vantard N, Ghergus D, Golfier C, Sesques P, Lazareth A, Lequeu H, Ferrant E, Salles G, Nicolas-Virelizier E, Ghesquieres H. Aussedat G, et al. Among authors: vantard n. Leuk Lymphoma. 2022 Mar;63(3):599-607. doi: 10.1080/10428194.2021.1998483. Epub 2021 Oct 31. Leuk Lymphoma. 2022. PMID: 34720034
Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program.
Charra F, Philippe M, Herledan C, Caffin AG, Larbre V, Baudouin A, Schwiertz V, Vantard N, Labussiere-Wallet H, Ducastelle-Leprêtre S, Barraco F, Balsat M, Larcher MV, Salles G, Rioufol C, Ranchon F. Charra F, et al. Among authors: vantard n. J Oncol Pharm Pract. 2021 Mar 8:10781552211000115. doi: 10.1177/10781552211000115. Online ahead of print. J Oncol Pharm Pract. 2021. PMID: 33683151
Administration of anticancer drugs: exposure in hospital nurses.
Rioufol C, Ranchon F, Schwiertz V, Vantard N, Joue E, Gourc C, Gauthier N, Guedat MG, Salles G, Souquet PJ, Favier B, Gilles L, Freyer G, You B, Trillet-Lenoir V, Guitton J. Rioufol C, et al. Among authors: vantard n. Clin Ther. 2014 Mar 1;36(3):401-7. doi: 10.1016/j.clinthera.2014.01.016. Epub 2014 Mar 5. Clin Ther. 2014. PMID: 24612942
Hypersensitivity to oxaliplatin: clinical features and risk factors.
Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, Gourc C, Gauthier N, Guedat MG, He S, Kiouris E, Alloux C, Vial T, Trillet-Lenoir V, Freyer G, Berard F, Rioufol C. Parel M, et al. Among authors: vantard n. BMC Pharmacol Toxicol. 2014 Jan 13;15:1. doi: 10.1186/2050-6511-15-1. BMC Pharmacol Toxicol. 2014. PMID: 24417770 Free PMC article.
Predictors of prescription errors involving anticancer chemotherapy agents.
Ranchon F, Moch C, You B, Salles G, Schwiertz V, Vantard N, Franchon E, Dussart C, Henin E, Colomban O, Girard P, Freyer G, Rioufol C. Ranchon F, et al. Among authors: vantard n. Eur J Cancer. 2012 May;48(8):1192-9. doi: 10.1016/j.ejca.2011.12.031. Epub 2012 Jan 28. Eur J Cancer. 2012. PMID: 22285178
31 results